Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 349

1.

Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease.

Al Draiweesh S, Ma C, Alkhattabi M, McDonald C, Nguyen TM, Beaton M, Chande N, Colquhoun P, Feagan BG, Gregor JC, Khanna R, Marotta P, Ponich T, Quan D, Qumosani K, Sandhu A, Sey M, Skaro A, Teriaky A, Wilson A, Yan B, Brahmania M, Jairath V.

Inflamm Bowel Dis. 2019 Oct 28. pii: izz244. doi: 10.1093/ibd/izz244. [Epub ahead of print]

PMID:
31665288
2.

Global burden of inflammatory bowel disease.

Jairath V, Feagan BG.

Lancet Gastroenterol Hepatol. 2019 Oct 21. pii: S2468-1253(19)30358-9. doi: 10.1016/S2468-1253(19)30358-9. [Epub ahead of print] No abstract available.

3.

Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease.

Lewis JD, Rutgeerts P, Feagan BG, D'haens G, Danese S, Colombel JF, Reinisch W, Rubin DT, Selinger C, Bewtra M, Barcomb L, Lacerda AP, Wallace K, Butler JW, Wu M, Zhou Q, Liao X, Sandborn WJ.

Inflamm Bowel Dis. 2019 Oct 23. pii: izz241. doi: 10.1093/ibd/izz241. [Epub ahead of print]

PMID:
31644790
4.

Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort.

Rahman A, Jairath V, Feagan BG, Khanna R, Shariff SZ, Allen BN, Jenkyn KB, Vinden C, Jeyarajah J, Mosli M, Benchimol E.

Aliment Pharmacol Ther. 2019 Nov;50(10):1086-1093. doi: 10.1111/apt.15511. Epub 2019 Oct 17.

PMID:
31621934
5.

Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials.

Pai RK, Kleiner DE, Hart J, Adeyi OA, Clouston AD, Behling CA, Jain D, Kakar S, Brahmania M, Burgart L, Batts KP, Valasek MA, Torbenson MS, Guindi M, Wang HL, Ajmera V, Adams LA, Parker CE, Feagan BG, Loomba R, Jairath V.

Aliment Pharmacol Ther. 2019 Nov;50(10):1100-1111. doi: 10.1111/apt.15503. Epub 2019 Oct 3.

PMID:
31583739
6.

Alternative and Complementary Approaches for the Treatment of Inflammatory Bowel Disease: Evidence From Cochrane Reviews.

Chande N, Costello SP, Limketkai BN, Parker CE, Nguyen TM, Macdonald JK, Feagan BG.

Inflamm Bowel Dis. 2019 Sep 27. pii: izz223. doi: 10.1093/ibd/izz223. [Epub ahead of print] No abstract available.

PMID:
31560744
7.

Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis.

Ma C, Sandborn WJ, D'Haens GR, Zou G, Stitt LW, Singh S, Ananthakrishnan AN, Dulai PS, Khanna R, Jairath V, Feagan BG.

Clin Gastroenterol Hepatol. 2019 Sep 20. pii: S1542-3565(19)31027-4. doi: 10.1016/j.cgh.2019.09.021. [Epub ahead of print]

PMID:
31546056
8.

Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease.

George J, Singh S, Dulai PS, Ma C, Nguyen T, Feagan BG, Sandborn WJ, Jairath V.

Inflamm Bowel Dis. 2019 Aug 30. pii: izz193. doi: 10.1093/ibd/izz193. [Epub ahead of print]

PMID:
31504528
9.

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.

Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, Tuttle JL, Klekotka P, Friedrich S, Durante M, Morgan-Cox M, Laskowski J, Schmitz J, D'Haens GR.

Gastroenterology. 2019 Sep 4. pii: S0016-5085(19)41300-0. doi: 10.1053/j.gastro.2019.08.043. [Epub ahead of print]

10.

Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review.

Gordon IO, Bettenworth D, Bokemeyer A, Srivastava A, Rosty C, Hertogh GE, Robert ME, Valasek MA, Mao R, Kurada S, Harpaz N, Borralho P, Pai RK, Pai RK, Odze R, Feakins R, Parker CE, Nguyen T, Jairath V, Baker ME, Bruining DH, Fletcher JG, Feagan BG, Rieder F; Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium.

Gastroenterology. 2019 Aug 30. pii: S0016-5085(19)41258-4. doi: 10.1053/j.gastro.2019.08.033. [Epub ahead of print]

PMID:
31476299
11.

Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease.

Ma C, Gecse KB, Duijvestein M, Sandborn WJ, Zou G, Shackleton LM, Stitt LW, Parker CE, Bossuyt P, Löwenberg M, Khanna R, Vermeire S, Rutgeerts P, Feagan BG, Jairath V, D'Haens GR.

Clin Gastroenterol Hepatol. 2019 Aug 29. pii: S1542-3565(19)30921-8. doi: 10.1016/j.cgh.2019.08.046. [Epub ahead of print]

PMID:
31473359
12.

Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data from 5 Randomized Controlled Induction Trials.

Duijvestein M, Jeyarajah J, Guizzetti L, Zou G, Parker CE, van Viegen T, VandeCasteele N, Khanna R, Van Der Aa A, Sandborn WJ, Feagan BG, D'Haens GR, Jairath V.

Clin Gastroenterol Hepatol. 2019 Aug 20. pii: S1542-3565(19)30900-0. doi: 10.1016/j.cgh.2019.08.025. [Epub ahead of print]

PMID:
31442599
13.

Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art Review.

de Rooij WE, Dellon ES, Parker CE, Feagan BG, Jairath V, Ma C, Bredenoord AJ.

Drugs. 2019 Sep;79(13):1419-1434. doi: 10.1007/s40265-019-01173-2. Review.

PMID:
31352605
14.

Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease.

Hindryckx P, Jairath V, Zou G, Feagan BG, Sandborn WJ, Stoker J, Khanna R, Stitt L, van Viegen T, Shackelton LM, Taylor SA, Santillan C, Mearadji B, D'Haens G, Richard MP, Panes J, Rimola J.

Gastroenterology. 2019 Nov;157(5):1233-1244.e5. doi: 10.1053/j.gastro.2019.07.027. Epub 2019 Jul 20.

PMID:
31336124
15.

What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?

Ma C, Battat R, Khanna R, Parker CE, Feagan BG, Jairath V.

Best Pract Res Clin Gastroenterol. 2019 Feb - Apr;38-39:101602. doi: 10.1016/j.bpg.2019.02.004. Epub 2019 Feb 22. Review.

PMID:
31327404
16.

IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?

Ma C, Panaccione R, Khanna R, Feagan BG, Jairath V.

Best Pract Res Clin Gastroenterol. 2019 Feb - Apr;38-39:101604. doi: 10.1016/j.bpg.2019.02.006. Epub 2019 Feb 19. Review.

PMID:
31327402
17.

Innovations in Oral Therapies for Inflammatory Bowel Disease.

Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V.

Drugs. 2019 Aug;79(12):1321-1335. doi: 10.1007/s40265-019-01169-y. Review.

PMID:
31317509
18.

Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.

Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG.

Gastroenterology. 2019 Oct;157(4):1007-1018.e7. doi: 10.1053/j.gastro.2019.06.038. Epub 2019 Jul 4.

19.

Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.

Li K, Friedman JR, Chan D, Pollack P, Yang F, Jacobstein D, Brodmerkel C, Gasink C, Feagan BG, Sandborn WJ, Rutgeerts P, De Hertogh G.

Gastroenterology. 2019 Oct;157(4):1019-1031.e7. doi: 10.1053/j.gastro.2019.06.037. Epub 2019 Jul 4.

20.

Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease.

D'Haens G, Rieder F, Feagan BG, Higgins PDR, Panes J, Maaser C, Rogler G, Löwenberg M, van der Voort R, Pinzani M, Peyrin-Biroulet L, Danese S; IOIBD Fibrosis Working Group.

Gastroenterology. 2019 Jun 26. pii: S0016-5085(19)41035-4. doi: 10.1053/j.gastro.2019.05.072. [Epub ahead of print]

PMID:
31254502
21.

Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn's Disease.

Turpin W, Espin-Garcia O, Bedrani L, Madsen K, Meddings JB, Raygoza Garay JA, Silverberg MS, Smith MI, Griffiths AM, Moayyedi P, Marshall JK, Mack D, Seidman EG, Ropeleski M, Feagan BG, Jacobson K, Turner D, Walters T, Paterson AD; CCC GEM Project Research Consortium , Xu W, Croitoru K.

Inflamm Bowel Dis. 2019 Oct 18;25(11):1796-1804. doi: 10.1093/ibd/izz116.

PMID:
31251335
22.

IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.

Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S.

J Crohns Colitis. 2019 Jun 3. pii: jjz110. doi: 10.1093/ecco-jcc/jjz110. [Epub ahead of print]

PMID:
31158271
23.

Editorial: combination immunosuppressive therapy to treat Crohn's disease - ready for all age groups? Authors' reply.

Singh S, Jairath V, Lw S, G Z, R K, Ps D, Wj S, Bg F.

Aliment Pharmacol Ther. 2019 Jun;49(12):1529. doi: 10.1111/apt.15283. No abstract available.

PMID:
31134649
24.

Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.

Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, Vande Casteele N, Khanna R, Panaccione R, Feagan BG, Jairath V.

Aliment Pharmacol Ther. 2019 Jul;50(1):5-23. doi: 10.1111/apt.15297. Epub 2019 May 23. Review.

PMID:
31119766
25.

Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Ma C, Panaccione NR, Nguyen TM, Guizzetti L, Parker CE, Hussein IM, Vande Casteele N, Khanna R, Dulai PS, Singh S, Feagan BG, Jairath V.

J Crohns Colitis. 2019 Sep 19;13(9):1201-1216. doi: 10.1093/ecco-jcc/jjz087.

PMID:
31111881
26.

Efficacy and Speed of Induction of Remission of Infliximab vs Golimumab for Patients With Ulcerative Colitis, Based on Data From Clinical Trials.

Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V.

Clin Gastroenterol Hepatol. 2019 May 17. pii: S1542-3565(19)30529-4. doi: 10.1016/j.cgh.2019.05.019. [Epub ahead of print]

PMID:
31108227
27.

Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.

Sands BE, Taub PR, Armuzzi A, Friedman GS, Moscariello M, Lawendy N, Pedersen RD, Chan G, Nduaka CI, Quirk D, Salese L, Su C, Feagan BG.

Clin Gastroenterol Hepatol. 2019 May 8. pii: S1542-3565(19)30491-4. doi: 10.1016/j.cgh.2019.04.059. [Epub ahead of print]

28.

The role of imaging in determining prognosis for primary sclerosing cholangitis: A systematic review.

Segal D, Marotta P, Mosli M, Zou G, Feagan BG, Al-Judaibi B.

Saudi J Gastroenterol. 2019 May-Jun;25(3):152-158. doi: 10.4103/sjg.SJG_478_18.

29.

Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.

Singh S, Proudfoot J, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ.

Am J Gastroenterol. 2019 Jun;114(6):1010. doi: 10.14309/ajg.0000000000000254. No abstract available.

PMID:
31033520
30.

Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease.

Novak G, Stevens T, Van Viegen T, Bossuyt P, Štabuc B, Jeyarajah J, Zou G, Gaemers IC, McKee TD, Fu F, Shackelton LM, Khanna R, van den Brink GR, Sandborn WJ, Feagan BG, Pai RK, Jairath V, Vande Casteele N, D'Haens G.

Aliment Pharmacol Ther. 2019 Jun;49(11):1401-1409. doi: 10.1111/apt.15250. Epub 2019 Apr 15.

PMID:
30983024
31.

Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review.

Bettenworth D, Bokemeyer A, Baker M, Mao R, Parker CE, Nguyen T, Ma C, Panés J, Rimola J, Fletcher JG, Jairath V, Feagan BG, Rieder F; Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium.

Gut. 2019 Jun;68(6):1115-1126. doi: 10.1136/gutjnl-2018-318081. Epub 2019 Apr 3.

32.

Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT.

Singh S, Stitt LW, Zou G, Khanna R, Dulai PS, Sandborn WJ, Feagan BG, Jairath V.

Aliment Pharmacol Ther. 2019 May;49(9):1188-1194. doi: 10.1111/apt.15214. Epub 2019 Mar 19.

PMID:
30891808
33.

Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.

Battat R, Ma C, Jairath V, Khanna R, Feagan BG.

Drug Saf. 2019 May;42(5):617-632. doi: 10.1007/s40264-018-00783-1. Review.

PMID:
30830573
34.

Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease?

Ma C, Battat R, Parker CE, Khanna R, Jairath V, Feagan BG.

Expert Rev Gastroenterol Hepatol. 2019 Apr;13(4):319-330. doi: 10.1080/17474124.2019.1563481. Epub 2019 Jan 3. Review.

PMID:
30791776
35.

Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews.

East JE, Boyapati RK, Torres J, Parker CE, MacDonald JK, Chande N, Feagan BG.

Inflamm Bowel Dis. 2019 Feb 21;25(3):472-478. doi: 10.1093/ibd/izy268.

PMID:
30789982
36.

Antibiotics for induction and maintenance of remission in Crohn's disease.

Townsend CM, Parker CE, MacDonald JK, Nguyen TM, Jairath V, Feagan BG, Khanna R.

Cochrane Database Syst Rev. 2019 Feb 7;2:CD012730. doi: 10.1002/14651858.CD012730.pub2.

PMID:
30731030
37.

Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Battat R, Duijvestein M, Guizzetti L, Choudhary D, Boland BS, Dulai PS, Parker CE, Nguyen TM, Singh S, Vande Casteele N, Pai RK, Feagan BG, Sandborn WJ, Jairath V.

Am J Gastroenterol. 2019 May;114(5):733-745. doi: 10.14309/ajg.0000000000000111.

PMID:
30694863
38.

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.

Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, Porter B, Das Gupta A, Pricop L, Fox T.

Ann Rheum Dis. 2019 Apr;78(4):473-479. doi: 10.1136/annrheumdis-2018-214273. Epub 2019 Jan 23.

39.

Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis.

Vande Casteele N, Jeyarajah J, Jairath V, Feagan BG, Sandborn WJ.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1814-1821.e1. doi: 10.1016/j.cgh.2018.10.036. Epub 2018 Oct 26.

PMID:
30613004
40.

Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies.

Ma C, Guizzetti L, Cipriano LE, Parker CE, Nguyen TM, Gregor JC, Chande N, Feagan BG, Jairath V.

Aliment Pharmacol Ther. 2019 Feb;49(4):364-374. doi: 10.1111/apt.15090. Epub 2018 Dec 19. Review.

PMID:
30569460
41.

Editorial: treating strictures in inflammatory bowel disease-authors' reply.

Rieder F, Feagan BG, Jairath V; CONSTRICT study group.

Aliment Pharmacol Ther. 2018 Dec;48(11-12):1313-1314. doi: 10.1111/apt.15032. No abstract available.

PMID:
30488620
42.

Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.

Sandborn WJ, Cyrille M, Hansen MB, Feagan BG, Loftus EV Jr, Rogler G, Vermeire S, Cruz ML, Yang J, Boedigheimer MJ, Abuqayyas L, Evangelista CM, Sullivan BA, Reinisch W.

Gastroenterology. 2019 Mar;156(4):946-957.e18. doi: 10.1053/j.gastro.2018.11.035. Epub 2018 Nov 23.

43.

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.

Feagan BG, Lam G, Ma C, Lichtenstein GR.

Aliment Pharmacol Ther. 2019 Jan;49(1):31-40. doi: 10.1111/apt.14997. Epub 2018 Nov 8. Review.

44.

Definitions of response and remission for the Robarts Histopathology Index.

Pai RK, Khanna R, D'Haens GR, Sandborn WJ, Jeyarajah J, Feagan BG, Vande Casteele N, Jairath V.

Gut. 2019 Nov;68(11):2101-2102. doi: 10.1136/gutjnl-2018-317547. Epub 2018 Oct 26. No abstract available.

PMID:
30366909
45.

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis.

Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S.

Inflamm Bowel Dis. 2019 May 4;25(6):1028-1035. doi: 10.1093/ibd/izy323.

46.

A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score.

Jairath V, Jeyarajah J, Zou G, Parker CE, Olson A, Khanna R, D'Haens GR, Sandborn WJ, Feagan BG.

Lancet Gastroenterol Hepatol. 2019 Jan;4(1):63-70. doi: 10.1016/S2468-1253(18)30306-6. Epub 2018 Oct 18.

PMID:
30343116
47.

Identifying Outcomes in Clinical Trials of Fistulizing Crohn's Disease for the Development of a Core Outcome Set.

Ma C, Parker CE, Nguyen TM, Khanna R, Feagan BG, Jairath V.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1904-1908. doi: 10.1016/j.cgh.2018.10.004. Epub 2018 Oct 4.

PMID:
30292887
48.

Identifying Outcomes in Clinical Trials of Pouchitis for the Development of a Core Outcome Set.

Ma C, Athayde J, Davies SC, Parker CE, Nguyen TM, Khanna R, Feagan BG, Jairath V.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1637-1640. doi: 10.1016/j.cgh.2018.09.042. Epub 2018 Sep 27.

PMID:
30268563
49.

Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials.

Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT.

J Crohns Colitis. 2019 Jan 1;13(1):50-57. doi: 10.1093/ecco-jcc/jjy125.

50.

Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial.

Jairath V, Peyrin-Biroulet L, Zou G, Mosli M, Vande Casteele N, Pai RK, Valasek MA, Marchal-Bressenot A, Stitt LW, Shackelton LM, Khanna R, D'Haens GR, Sandborn WJ, Olson A, Feagan BG, Pai RK.

Gut. 2019 Jul;68(7):1162-1168. doi: 10.1136/gutjnl-2018-316702. Epub 2018 Aug 3.

PMID:
30076171

Supplemental Content

Loading ...
Support Center